For adult and pediatric patients 6 years of age and older weighing at least 45kg, the maximum daily dosage has been increased from 80mg to 100mg. The Food and Drug Administration (FDA) has ...

The FDA has approved amifampridine tablets for the treatment of adult patients with Lambert-Eaton myasthenic syndrome, according to a press release.Characterized by autonomic changes, depressed ...

Results from the Phase 3 trial showed that the Quantitative Myasthenia Gravis (QMG) score at baseline to day 14 changed from 6.4 to 6.7 in the amifampridine group vs. 5.6 to 7.9 for the placebo group.

In the case we describe, the electromyogram (EMG) showed that the initial low-amplitude potential was at 0.54 mV and increased progressively to 1.82 mV, a change of 237%. This EMG pattern is a ...

Myasthenia gravis (MG) and Lambert-Eaton syndrome, also known as Lambert-Eaton myasthenic syndrome (LEMS), are two autoimmune disorders that attack your muscles.

BLAINVILLE, QC, Sept. 25, 2020 /CNW Telbec/ - Médunik Canada, a pharmaceutical company dedicated to improving the health and quality of life of Ca ...

Patients with nontumor Lambert-Eaton myasthenic syndrome had survival rates comparable to the general population, according to the results of an observational study conducted in the Netherlands.

Patients experiencing isolated dysphagia may be showing early signs of a rare condition called Lambert-Eaton myasthenic syndrome (LEMS), according to a letter to the editor published on March 12 in ...

SILVER SPRING, Md., May 6, 2019 /PRNewswire/ -- The U.S. Food and Drug Administration today approved Ruzurgi (amifampridine) tablets for the treatment of Lambert-Eaton myasthenic syndrome (LEMS ...

The FDA has granted approval to the first treatment for children with Lambert-Eaton myasthenic syndrome (LEMS), a rare autoimmune disorder.The drug, amifampridine (Ruzurgi), is approved for the ...